2-(2-(吡啶-3-基)二硫烷基)吡啶 | 1056935-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(2-(吡啶-3-基)二硫烷基)吡啶
• 英文名称: 2,2′-dithiodipyridine
• 英文别名: 2,2'-dipyridyl disulfide；2-(2-(Pyridin-3-yl)disulfanyl)pyridine；2-(pyridin-3-yldisulfanyl)pyridine
• CAS: 1056935-09-1
• 化学式: C₁₀H₈N₂S₂
• 分子量: 220.319
• InChiKey: NUMGEMJDCLWFBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-(吡啶-3-基)二硫烷基)吡啶 、 5-bromo-3-phenoxypyridin-2-amine 在 甲基锂 、 正丁基锂 、 甲醇 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 生成 3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-amine
  参考文献：
  名称：

  WO2008/118718

  摘要：

  公开号：
• 作为试剂：
  描述：

  咪唑 、 7-methyl-3'-mesyloxyguanosine-5'-diphosphate triethylammonium 在 2-(2-(吡啶-3-基)二硫烷基)吡啶 、 三乙胺 、 三苯基膦 、 sodium perchlorate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 以100 %的产率得到7-methyl-3'-mesyloxyguanosine-5'-diphosphate imidazolide
  参考文献：
  名称：

  WO2023/191342

  摘要：

  公开号：

文献信息

• Redox responsive Pd(<scp>ii</scp>) templated rotaxane nanovalve capped mesoporous silica nanoparticles: a folic acid mediated biocompatible cancer-targeted drug delivery system
  作者：Srivardhan Reddy Gayam、Shu-Pao Wu

  DOI：10.1039/c4tb01030b

  日期：——

  Herein, redox responsive Pd(ii) templated rotaxane nanovalve capped mesoporous silica nanoparticles were designed for an effective cancer-targeted drug delivering system.

  在这里，设计了一种氧化还原响应的Pd(II)模板化轮烷纳米阀盖的介孔硅纳米颗粒，用于有效的针对癌症的药物传递系统。
• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas D.

  公开号：US20090156603A1

  公开（公告）日：2009-06-18

  Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了化学式I的化合物，这些化合物在治疗和/或预防由胰岛素活性不足引起的疾病中非常有用，例如糖尿病。还提供了治疗或预防由胰岛素活性不足或可以通过激活胰岛素来治疗的疾病和疾患的方法。
• Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：Aicher Thomas Daniel

  公开号：US20100204240A1

  公开（公告）日：2010-08-12

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供的化合物式(I)如下：其中R2、R3、R13、L和D2如规范中所定义，这些化合物可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或紊乱，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及本文所讨论的其他疾病和紊乱。
• Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：AICHER Thomas Daniel

  公开号：US20120277242A1

  公开（公告）日：2012-11-01

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  本发明提供了式(I)的化合物：其中R2、R3、R13、L和D2如规范中所定义，它们在治疗和/或预防由葡萄糖激酶活性不足介导的疾病或疾病中有用，或者可以通过激活葡萄糖激酶来治疗，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及其他疾病和疾病，如在此处所讨论的。
• Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
  申请人：Array BioPharma, Inc.

  公开号：US08212045B2

  公开（公告）日：2012-07-03

  Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供的化合物式(I)如下：其中R2、R3、R13、L和D2如规范中所定义，可用于治疗和/或预防由于葡萄糖激酶活性不足而介导的疾病或疾病，或可通过激活葡萄糖激酶来治疗，包括但不限于糖尿病、糖耐量受损、空腹血糖受损(IFG)和空腹高血糖(IFG)，以及其他在此处讨论的疾病和紊乱。